Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).
Gastric cancer (GC) has a high global incidence and mortality rate [...].
APA
Zheng B, Lou F, et al. (2025). Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).. Cancers, 17(4). https://doi.org/10.3390/cancers17040657
MLA
Zheng B, et al.. "Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).." Cancers, vol. 17, no. 4, 2025.
PMID
40002252
Abstract
Gastric cancer (GC) has a high global incidence and mortality rate [...].
같은 제1저자의 인용 많은 논문 (5)
- LncRNA SLC16A1-AS1 cooperates with NSUN2 to stabilize GRP78 mRNA via m5C modification in gastric cancer.
- Metabolic burden-based clinical-radiological model for predicting postoperative recurrence of hepatitis B-related hepatocellular carcinoma.
- Lentiviral Dendritic Cell Vaccine Targeting Claudin-18.2 Elicits Potent Antitumor Immunity Against Gastric Cancer.
- Role of matrix metalloproteinases in the invasion of glioblastoma and drug interventions (Review).
- Claudin18.2 promote gastric cancer proliferation by activating MCM2/5.